On behalf of the organizing committee, we invite you to attend and speak at the Fifth Ling-Nan International Forum on DMPK to be hosted by the School of Pharmaceutical Sciences at Sun Yat-sen University, School of Pharmaceutical Sciences at Southern Medical University, and Guangdong Pharmacological Society on Nov 10-12, 2023 in Guangzhou, China.

This event is designed to offer a forum for global learning, accelerating intellectual exchange, bringing participants to the frontier of drug metabolism and pharmacokinetics research, and promoting international collaboration in DMPK sciences. The theme of this forum is “exchange, collaboration, and development”. We believe that the group of invited speakers, representing both renowned domestic and international DMPK experts, will inspire the attendees with new research ideas, bring fresh insights, integrate different resources, create collaborative opportunities, and promote the development of DMPK.

This will once again be a great academic event in the field of DMPK. We cordially invite colleagues from universities, research institutes, and industry to participate in the Fifth Ling-Nan International DMPK Forum in 2023. We are looking forward to seeing you in Guangzhou!

1. About the forum 

The forum will include

1) Panel discussions exploring new scientific questions on DMPK

2) Invited lectures by domestic and international DMPK experts.

3) Young scholars presenting their latest research findings

4) Meeting to enhance communication and collaboration.

Symposia topics include but are not limited to, the following topics 

1）New advances in DMPK research；

2）Drug metabolism and drug toxicology；

3）Regulatory mechanism of drug metabolism

4) Other scientific issues related to DMPK

2. Scientific Advisory Board

Co-Chairs:  

Domestic: Min Huang (Sun Yat-sen University, China), HuiChang Bi (Southern Medical University, China)

International: Xin-Xin Ding (University of Arizona USA)

Members:

Jing-Kai Gu (Jilin University, China)

Chuan Li (Shanghai Institute of Material Medica, China))

Ge Lin (The Chinese University of Hong Kong, China)

Wen Xie (University of Pittsburgh, USA)

Ai-Ming Yu (University of California at Davis, USA)

Su Zeng (Zhejiang University, China)

Xiao-Bo Zhong (University of Connecticut, USA)

Zhong Zuo (The Chinese University of Hong Kong, China)

3. Meeting Program 

4. Call for Abstracts

The conference welcomes the submission of abstracts that fit with the theme of this event from post-doctors or graduate students. Outstanding abstracts will be selected and presented as a poster or oral presentation. Both the abstracts and posters should be in English. The poster presentation will take place during the conference. Please refer to the attached for the format of the abstract.

5. Registration

The registration is conducted online. Please scan the QR code below to register. Participants are kindly requested to complete the online registration before November 9, 2023. The QR code for conference registration is as follows:

6. Currently invited speakers 

Aiming Yu (University of Califoria at Davis, USA)

Andrew Paterson (Penn State University, USA)

Baojian Wu (Guangzhou University of Chinese Medicine, China)

Benzhan Zhu (Chinese Academy of Sciences, China)

Chuan Li (Shanghai Institute of Material Medica, China)

Dafang Zhong (Shanghai Institute of Material Medica, China)

Eric Chan (National University of Singapore, Singapore)

Feng Zhu (Zhejiang University, China)

Ge Lin (The Chinese University of Hong Kong, China)

Grace L Guo (Rutgers University, USA)

Guangbo Ge (Shanghai University of Traditional Chinese Medicine, China)

Guofeng You (Rutgers University, USA)

Huichang Bi (Southern Medical University, China)

Huidi Jiang (Zhejiang University, China)

Hongbing Wang (University of Maryland, USA)

Herana K. Seneviratne (University of Maryland Baltimore Country, USA)

José E. Manautou (University of Connecticut, USA)

Jiang Zheng (Shenyang Pharmaceutical University/Guizhou Medical University, China)

Jingkai Gu (Jilin University, China)

Lauren Aleksunes (Rutgers University, USA)

Lirong Zhang (Zhengzhou University, China)

Lynn Ge (The Chinese University of Hong Kong, China)

Qingyu Zhang (University of Amrizona, USA）

Taosheng Chen (St. John's Children's Reseach Hospital, USA)

Wei Jia (Hongkong Baptist University, China)

Wei Yue (University of Oklahoma Health Sciences Center, USA)

Wen Xie (University of Pittsburgh, USA)

Xiaobo Zhong (University of Connecticut, USA)

Xiaochao Ma (University of Pittsburgh, USA)

Xinxin Ding (University of Arizona, USA)

Yan Shu (University of Maryland, USA)

Zhong Zuo (The Chinese University of Hong Kong, China)

                     The organizing committee of

The Fifth Ling-Nan International Forum on DMPK

                                                                                                       September 8, 2023

 Abstract template

Fenofibrate induced-hepatomegaly and liver regeneration is PPARα- dependent and partially related to the activation of YAP pathway

Shicheng Fan¹, Yue Gao², Min Huang^2*, Huichang Bi^1*

¹ School of Pharmaceutical Sciences, Southern Medical University

² School of Pharmaceutical Sciences, Sun Yat-sen University

Fenofibrate, an agonist of peroxisome proliferator-activated receptor α (PPARα), has been widely used as a lipid-regulating agent in clinical practice. Recent studies found that fenofibrate treatment induced hepatomegaly in mice, but the mechanisms involved remain unclear. YAP, the key effector of Hippo signaling pathway, plays an important role in manipulating the liver size and regeneration. The aim of this study is to identify the role of YAP in fenofibrate-induced hepatomegaly and liver regeneration. The effects of fenofibrate on liver enlargement and liver regeneration were investigated in wild-type, Pparafl/fl, and hepatocyte-specific Ppara-deficient (PparaΔHep) mice. The results showed that administration of fenofibrate significantly induced liver enlargement and promoted liver regeneration after partial hepatectomy, accompanied by hepatocyte hypertrophy around the central vein area and enhanced hepatocyte proliferation around the portal vein area. Mechanistically, fenofibrate regulated the expressions of YAP and its downstream targets. Fenofibrate activated YAP signaling via suppressing K48-linked ubiquitination and promoting K63-linked ubiquitination, and enhancing interaction and transcriptional activity of YAP-TEAD complex. Suppression of YAP using AAV-Yap shRNA in mice significantly attenuated fenofibrate-induced hepatomegaly, as well as hepatocyte hypertrophy and proliferation. Other factors might also participate in fenofibrate-induced hepatomegaly, including MYC, KRT23, RHOA, and RAS. These studies revealed a novel role of fenofibrate in promoting liver enlargement and regeneration partially through activating the YAP signaling pathway. These findings provide clinical implications of fenofibrate as a potential medication for promoting liver regeneration following PHx.

Key Words

Fenofibrate; peroxisome proliferator-activated receptor α; hepatomegaly; liver regeneration; yes-associated protein

Please send your abstract to lingnanDMPK2023@163.com.